OS Therapies Partners with B2i Digital to Enhance Investor Outreach

OS Therapies, Inc. , a clinical-stage biotechnology company, has teamed up with B2i Digital to boost their engagement with investors. B2i Digital, a company specializing in digital marketing technologies and investor conferences, will utilize data-driven strategies to increase awareness about OS Therapies' groundbreaking research and upcoming milestones, such as the potentially pivotal Phase 2b clinical trial for OST-HER2 in recurrent, resected metastatic osteosarcoma.

B2i Digital will place a spotlight on OS Therapies' lead candidate, OST-HER2, an off-the-shelf immunotherapy designed to activate the immune system to target HER2-positive cancer cells. The Phase 2b trial for OST-HER2 has completed enrollment and all patient visits, with the next clinical data update expected to be revealed during the week of the JP Morgan Healthcare Conference 2025.  Apart from the Phase 2b trial, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC). This platform leverages the Company's proprietary silicone linker technology, enabling the delivery of multiple payloads per linker.